Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
Seventy-nine patients with metastatic melanoma received chlorozotocin (150 mg/m2) every 6 weeks. Two complete and five partial responses were observed: 18% in patients who had not previously received chemotherapy and 6% in previously drug-resistant patients. Dose-limiting toxic effects were vomiting and myelosuppression.
D004341:Drug Evaluation; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008545:Melanoma / Q000188:drug therapy*; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000188:drug therapy*; D013311:Streptozocin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
C007028:chlorozotocin; D013311:Streptozocin